PubMed Health⌕ Search

Biomedical subjects

A Balbi

Publications and source records attributed to A Balbi.

48 records · Page 3Linked to original sources
PubMed1979

[Chemical and pharmacological research on pyran derivatives. XIV. 3-alkylaminoaphtho/2,1-b/pyran-1-ones and derivatives].

3-Alkyl(phenyl)aminoaphtho[2,1-b]pyran-1-ones (III) were prepared from N-alkyl or N-phenylethoxycarbonylacetamides and 2-naphthol in the presence of phosphorus oxychloride, in order to evaluate their pharmacological activity on the CNS in comparison with previously described 3-dialkylaminoaphtho[2,1-b]pyran-1-ones. Compounds (III) gave 2-morpholinomethyl derivatives as well as N-acetyl and N-ethtoxycarbonyl derivatives. The reaction of (III) in which R = alkyl and N,N-dimethylformamide-POCl3 afforded 2-formyl derivatives and in some cases also 8-alkyl-9,10-bisdimethylaminoaphtho[1',2':5,6]pyrano[2,3-b]pyrrol-11(8H)-ones; when R = phenyl, only naphtho[1',2':5,6]pyrano[2,3-b]quinolin-14-one was obtained from the same reaction. Pharmacological evaluation showed that compounds (III) had a weak CNS depressant activity. Some of them also exhibited antagonist effect on reserpine-induced blepharospasm and hypothermia and on metrazole-induced seizures in the mouse. Within the limits of these activities a special behavior was found for the compound 3-ethylaminoaphtho[2,1-b]pyran-1-one [(III b) - K 12479].

Amphetamines↗
PubMed1979

[1,5-Benzodiazepines. III. Synthesis of 2,4-bisdialkylamino-3H-1,5-benzodiazepines].

Treatment of 2,3-dihydro-2-oxo-4-dialkylamino-1H-1,5-benzodiazepines with phosphorus pentasulfide afforded 2-thio derivatives which in turn gave the corresponding methylmercapto derivatives by reaction with sodium hydride and methyl iodide. By treating these compounds with dialkylamines the formation of 2,4-bisdialkylamino-3H-1,5-benzodiazepines was achieved. Pharmacological screening of some of the products indicated that the introduction of a second dialkylamino substituent into the 1,5-benzodiazepine molecule gave the compounds CNS excitant properties, while the initial monodialkylamino derivatives containing sulfur showed a CNS depressant activity.

Amphetamine↗
PubMed1978

[Chemical and pharmaceutical research on pyran derivatives. X. Synthesis of 1-oxo-2-alkyl-3-dialkylamino-1H-naphtho[2,1b]pyrans].

When reaction of N,N-dialkyl-alpha-ethoxycarbonyl-alpha-alkylacetamides with beta-naphthol in the presence of phosphorus oxychloride was carried out in chlorobenzene at reflux, formation of 1-oxo-2-alkyl-3-dialkyl-amino-1H-naphtho[2,1-b]pyrans was achieved together with some other products whose structure was defined. Moreover, substitution of the 2 position of 1-oxo-3-dialkylamino-1H"naphtho[2,1-b]pyrans with chlorine or cyano group as well as the preparation of 1-thio-3-dialkylamino-1H-naphtho[2,1-b]pyrans was obtained by suitable chemical methods. Pharmacological screening of these compounds showed the lack of psychotropic activity of the corresponding 1-oxo-3-dialkylamino-1H-naphtho[2,1-b]pyrans.

Animals↗
PubMed1977

[Chemical and pharmacologic study on pyran derivatives. IX. Synthesis of 2-dialkylaminochromones].

Under suitable conditions the reaction of phenol and N,N-dialkylethoxycarbonylacetamides, in the presence of phosphorus oxychloride, resulted in the formation of 2-dialkylaminochromones. In a similar manner, variously substituted phenols afforded 2-dialkylaminochromones with substituents in different positions of the benzene ring. Pharmacological screening of all these compounds showed that they markedly affect the CNS, activity being mainly excitatory. Decreased activity was shown by compounds with particular substituents in the positions 6,7,8 among which two products [(V e) - K 12440, (V s) - K 12420] have weak but clear anticonvulsant effect.

Animals↗
PubMed1977

[Studies on 1,5-benzodiazepine. I. Derivatives of 4-amino-1,5-benzodiazepine].

Condensation of o-phenylendiamine and N,N-dialkyl-ethoxycarbonylacetamides in the presence of phosphorus oxychloride afforded 2,3-dihydro-2-oxo-4-dialkylamino-1H-1,5-benzodiazepines. These same compounds with a substituent in the 3 position were obtained when N,N-dialkylamino-alpha-ethoxycarbonyl-alpha-alkylacetamides were employed in the reaction. In a similar manner from N-phenyl-o-phenylendiamine the synthesis of 1-phenyl-2,3-dihydro-2-oxo-4-dialkylamino-1H-1,5-benzodiazepines was achieved. The formation of benzimidazole-2-acetic acid derivatives was observed in these reactions.

Amines↗
PubMed1977

[Study of 1,5-benzodiazepines. II. Synthesis of 2,4-di-(N-alkyl,N-phenyl)amino-3H-1,5-benzodiazepine].

Following the procedure we described for synthesizing analogous compounds in Note I (7), reaction of N,N-dialkyl or (N-alkyl,N-phenyl)ethoxycarbonylacetamides with 4-chloro-1,2-phenylendiamine, in the presence of phosphorus oxychloride, afforded 2,3-dihydro-2-oxo-4-dialkyl (N-alkyl,N-phenyl)amino-chloro-1H-1,5-benzodiazepines. When a large amount of phosphorus oxychloride was employed in the reaction, the formation of 2,4-di-(N-alkyl,N-phenyl)amino-3H-1,5-benzodiazepines was achieved, starting from suitable o-phenylendiamines and (N-alkyl,N-phenyl)ethoxycarbonylacetamides. Pharmacological tests were carried out on some compounds described in the present paper and on others reported in the preceding Note (7); in this connection 4-amino-1,5-benzodiazepine derivatives showed weak CNS depressing activity in addition, in some cases, to clear, although moderate, anticonvulsant activity, whereas 2,4-diamino-1,5-benzodiazepine derivatives were practically without effect.

Animals↗
PubMed1976

[Chemical and pharmacological research on pyran derivatives. VI. 2-Dialkylamino-4-oxo-4H-naphto/1,2-b/pyrans and derivatives].

The 2-dialkylamino-4-oxo-4H-naphtho [1,2-b]pyrans are obtained by the reaction of N,N-dialkylethoxycarbonylacetamides with alpha-naphthol and with substituted alpha-naphthols. The products on treatment with formaldehyde and morpholine or piperidine or N-methylpiperazine are transformed into the 2-dialkylamino-3-dialkylaminomethyl-4-oxo-4H-naphtho [1,2-b]pyrans. Pharmacological investigation has shown that 2-dimethylamino (K 12164), 2-(N-ethyl, N-methyl)amino- (K 12087) and 2-diethylamino-4-oxox-4H-naphtho [1,2-b]pyran (K 12165) show clear neurotropic activity of the neuroleptic type whereas compounds of the isomeric series, 1H-naphtho-[2,1-b]pyrans, studied previously (1), show anticonvulsive and sedative activity. This difference in pharmacological activity has prompted a more complete comparative examination of the activity of the two series of compounds. Study of antagonism to the effects of reserpine by both 4H-naphtho [1,2-b]pyrans and 1H-naphtho [2,1-b]pyrans has shown that in the latter series the 1-oxo-3-dimethylamino- (K 8291), the 1-oxo-3-(N-ethyl, N-methyl)amino- (K 8409) and the 1-oxo-3-diethylamino-1H-naphtho [2,1-b]-pyran (K 8292) have marked neurotropic activity of the antidepressive type.

Antidepressive Agents↗
PubMedDate not supplied

Quantitative EEG effects and drug plasma concentration of phenobarbital, 50 and 100 mg single-dose oral administration to healthy volunteers: evidence of early CNS bioavailability.

Single, 50- and 100-mg oral doses of phenobarbital and a matching placebo were administered double-blind to 8 young, healthy male subjects. Multilead electroencephalographic (EEG) samples were recorded prior to, and at regular intervals within the 2 h following administration. The EEG signal was processed by power spectral analysis; the drug plasma concentration was assessed concomitantly. Plasma peaks after the 50- and 100-mg dose were, respectively, 3.38 +/- 1.29 and 4.09 +/- 1.24 micrograms/ml. Despite the low drug plasma concentration, a systematic power increment of the EEG fast frequency spectral segments occurred at either dose on the anterior scalp areas from the 30- or 60-min postdrug control onward, and was preponderant on central electrodes; a significant correlation (Kendal's coefficient for ranked data) with the drug plasma concentration was observed limitedly to the anterior scalp areas. No correlation with plasma levels was observed for unsystematic EEG variations.

Administration, Oral↗